推荐产品
等级
pharmaceutical primary standard
API类
dydrogesterone
制造商/商品名称
EDQM
应用
pharmaceutical (small molecule)
包装形式
neat
储存温度
2-8°C
SMILES字符串
O=C1CC[C@@]2([C@@H]3[C@H]([C@H]4[C@@]([C@H](CC4)C(=O)C)(CC3)C)C=CC2=C1)C
InChI
1S/C21H28O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h4-5,12,16-19H,6-11H2,1-3H3/t16-,17+,18-,19-,20-,21+/m0/s1
InChI key
JGMOKGBVKVMRFX-LEKSSAKUSA-N
正在寻找类似产品? 访问 产品对比指南
一般描述
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
应用
Dydrogesterone impurity B EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
包装
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他说明
Sales restrictions may apply.
法规信息
监管及禁止进口产品
Zahiruddin Othman et al.
Menopause (New York, N.Y.), 18(11), 1219-1224 (2011-09-20)
The aim of this study was to evaluate the verbal learning and memory performance of postmenopausal women who received tualang honey (Agro Mas) in comparison with women receiving estrogen plus progestin therapy and untreated controls. A total of 102 postmenopausal
Ashalatha Ganesh et al.
Fertility and sterility, 95(6), 1961-1965 (2011-02-22)
To compare the efficacy of oral dydrogesterone with that of micronized vaginal P gel and micronized P capsule for luteal supplementation. Prospective, randomized clinical study. Institute of Reproductive Medicine, Kolkata, India. A total of 1,373 infertile women undergoing IVF participated.
Changes in hemostatic parameters after oral and transdermal hormone therapy in postmenopausal women.
Ireneusz Polac et al.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 27(9), 692-695 (2010-10-29)
Hormone therapy (HT) can be prothrombotic risk factor. We compared the effects of oral HT (o-HT) and transdermal HT (t-HT) on the kinetic of clot formation and fibrinolysis in postmenopausal women after 6 months HT using a multiparameter test. We
M V Suknovalova et al.
Eksperimental'naia i klinicheskaia farmakologiia, 76(7), 24-26 (2013-09-07)
It has been shown that specific binding of dydrogesterone with progesterone receptors in blood mononuclear cells of the patients included in the programs of in vitro fertilization, varies from 0 to 298%, thus at 38% of women dydrogesterone concedes to
A J Scheen et al.
Revue medicale de Liege, 66(4), 209-214 (2011-06-07)
Femoston Low is a hormone replacement therapy that combines low dosages of steroids, i.e. 0.5 mg of estradiol and 2.5 mg of dydrogesterone. This oral preparation should be taken continuously to treat climacteric symptoms in menopausal women. Femoston Low is
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门